Compare BBGI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | GDTC |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.4M |
| IPO Year | 1999 | 2021 |
| Metric | BBGI | GDTC |
|---|---|---|
| Price | $22.89 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.5K | 12.0K |
| Earning Date | 04-08-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $232,179,463.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.56 | ★ N/A |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.14 | $0.68 |
| 52 Week High | $29.30 | $3.68 |
| Indicator | BBGI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 49.02 |
| Support Level | $3.72 | $0.93 |
| Resistance Level | $25.26 | $1.09 |
| Average True Range (ATR) | 2.02 | 0.07 |
| MACD | -0.59 | 0.00 |
| Stochastic Oscillator | 15.05 | 49.61 |
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.